Journal of Southern Medical University ›› 2026, Vol. 46 ›› Issue (9): 2113-2122.doi: 10.12122/j.issn.1673-4254.2026.09.11
Ai QIAN1(
), Chuanbing HUANG1,2(
), Yawen ZHU1, Kexin HU1, Xinran SONG1, Yuxiang XU1
Received:2026-02-02
Online:2026-09-20
Published:2026-09-30
Contact:
Chuanbing HUANG
E-mail:1838929252@qq.com;chuanbinh@163.com
Supported by:Ai QIAN, Chuanbing HUANG, Yawen ZHU, Kexin HU, Xinran SONG, Yuxiang XU. Qihuang Jianpi Zishen Granule ameliorates renal injury in patients with systemic lupus erythematosus by regulating immunometabolic reprogramming of macrophages[J]. Journal of Southern Medical University, 2026, 46(9): 2113-2122.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.j-smu.com/EN/10.12122/j.issn.1673-4254.2026.09.11
| Gene | Amplicon size (bp) | Forward primer (5'→3') | Reverse primer (5'→3') |
|---|---|---|---|
| β-actin | 96 | CCCTGGAGAAGAGCTACGAG | GGAAGGAAGGCTGGAAGAGT |
| AMPK | 99 | CTTCGGCAAAGTGAAGATTG | CCAACAACATCTAAACTGCG |
| mTOR | 178 | GGCCAATGACCCAACATCTC | CATGATGCGATGCTCGATGT |
| HIF-1α | 168 | TAAGAAACCACCTATGACCTGC | TCTGGCTCATATCCCATCAA |
| ULK1 | 88 | CTTTTGTTTCTCCGTTGGGG | GGGCTGCTAATCCGAATCC |
Tab.1 Primer sequences for RT-qPCR
| Gene | Amplicon size (bp) | Forward primer (5'→3') | Reverse primer (5'→3') |
|---|---|---|---|
| β-actin | 96 | CCCTGGAGAAGAGCTACGAG | GGAAGGAAGGCTGGAAGAGT |
| AMPK | 99 | CTTCGGCAAAGTGAAGATTG | CCAACAACATCTAAACTGCG |
| mTOR | 178 | GGCCAATGACCCAACATCTC | CATGATGCGATGCTCGATGT |
| HIF-1α | 168 | TAAGAAACCACCTATGACCTGC | TCTGGCTCATATCCCATCAA |
| ULK1 | 88 | CTTTTGTTTCTCCGTTGGGG | GGGCTGCTAATCCGAATCC |
| Ggene name | Protein name | Degree | Protein number |
|---|---|---|---|
| TP53 | Tumor protein p53 | 40 | Q12888 |
| MAPK1 | Mitogen-activated protein kinase 1 | 30 | O94737 |
| AKT1 | AKT Serine/Threonine Kinase 1 | 32 | Q38998 |
| HSP90AA1 | Heat shock protein90alpha family class A member1 | 24 | O94826 |
| IL-6 | Interleukin 6 | 30 | P05231 |
| ESR1 | Estrogen receptor 1 | 26 | P03372 |
| TNF | Tumor necrosis factor | 30 | Q9UNG2 |
| BCL2 | Apoptosis regulator Bcl-2 | 22 | Q9JJV8 |
| FOS | Protein c-Fos | 24 | O77628 |
Tab.2 Core target information
| Ggene name | Protein name | Degree | Protein number |
|---|---|---|---|
| TP53 | Tumor protein p53 | 40 | Q12888 |
| MAPK1 | Mitogen-activated protein kinase 1 | 30 | O94737 |
| AKT1 | AKT Serine/Threonine Kinase 1 | 32 | Q38998 |
| HSP90AA1 | Heat shock protein90alpha family class A member1 | 24 | O94826 |
| IL-6 | Interleukin 6 | 30 | P05231 |
| ESR1 | Estrogen receptor 1 | 26 | P03372 |
| TNF | Tumor necrosis factor | 30 | Q9UNG2 |
| BCL2 | Apoptosis regulator Bcl-2 | 22 | Q9JJV8 |
| FOS | Protein c-Fos | 24 | O77628 |
| Key ingtedients | Target | Affinity (kcal/mol) |
|---|---|---|
| Quercetin | HIF-1α | -7.0 |
| mTOR | -7.0 | |
| Kaempferol | HIF-1α | -7.0 |
| mTOR | -6.7 | |
| 7-O-methylisomucronulatol | HIF-1α | -6.7 |
| mTOR | -6.0 |
Tab.3 Molecular docking results of the active components against the core module targets
| Key ingtedients | Target | Affinity (kcal/mol) |
|---|---|---|
| Quercetin | HIF-1α | -7.0 |
| mTOR | -7.0 | |
| Kaempferol | HIF-1α | -7.0 |
| mTOR | -6.7 | |
| 7-O-methylisomucronulatol | HIF-1α | -6.7 |
| mTOR | -6.0 |
Fig.6 Molecular docking patterns between highly active components and the core module targets. A: HIF-1α+quercetin.B:mTOR+quercetin. C: HIF-1α+kaempferol.D: mTOR+kaempferol. E: HIF-1α+7-O-methylisomucronulatol.F: mTOR+7-O-methylisomucronulatol.
| Group | TCM syndrome scores | |
|---|---|---|
| Pre-treatment | Post-treatment | |
| Control | 22.29±2.27 | 16.87±1.77** |
| Observation | 21.32±2.21 | 12.68±1.49**△△ |
Tab.4 Comparison of TCM syndrome scores between the two groups of SLE patients (n=31, Mean±SD)
| Group | TCM syndrome scores | |
|---|---|---|
| Pre-treatment | Post-treatment | |
| Control | 22.29±2.27 | 16.87±1.77** |
| Observation | 21.32±2.21 | 12.68±1.49**△△ |
| Index | Control | Observation | ||
|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |
| CREA | 76.55±14.22 | 70.01±10.55** | 77.50±14.84 | 64.15±8.85**△△ |
| BUN | 13.95±3.85 | 8.45±1.45** | 13.03±3.35 | 6.50±1.45**△△ |
| eGFR | 93.36±15.30 | 109.78±17.02** | 93.60±20.46 | 124.50±30.50**△△ |
Tab.5 Comparison of CREA, BUN, eGFR between the two groups of SLE patients (n=31, Mean±SD)
| Index | Control | Observation | ||
|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |
| CREA | 76.55±14.22 | 70.01±10.55** | 77.50±14.84 | 64.15±8.85**△△ |
| BUN | 13.95±3.85 | 8.45±1.45** | 13.03±3.35 | 6.50±1.45**△△ |
| eGFR | 93.36±15.30 | 109.78±17.02** | 93.60±20.46 | 124.50±30.50**△△ |
| Index | Control | Observation | ||
|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |
| iNOS | 1.07±0.08 | 0.83±0.05** | 1.08±0.08 | 0.52±0.07**△△ |
| Arg-1 | 0.59±0.09 | 0.82±0.04** | 0.60±0.08 | 1.15±0.06**△△ |
Tab.6 Comparison of iNOS and Arg-1 between the two groups of SLE patients (n=31, Mean±SD)
| Index | Control | Observation | ||
|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |
| iNOS | 1.07±0.08 | 0.83±0.05** | 1.08±0.08 | 0.52±0.07**△△ |
| Arg-1 | 0.59±0.09 | 0.82±0.04** | 0.60±0.08 | 1.15±0.06**△△ |
Fig.7 Macrophage marker protein expression in the two groups of SLE patients. A: Control group (before treatment). B: Control group (after treatment). C: QJZG treatment group (before treatment). D: QJZG treatment group (after treatment).
| Index | Normal (n=30) | Control (n=31) | Observation (n=31) | |||
|---|---|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |
| AMPK | 1.65±0.61 | - | 0.86±0.22▲▲ | 1.26±0.55** | 0.93±0.22▲▲ | 1.50±0.24**△△ |
| mTOR | 0.73±0.27 | - | 1.17±0.27▲▲ | 1.00±0.07** | 1.24±0.27▲▲ | 0.85±0.13**△△ |
| HIF-1α | 0.45±0.10 | - | 0.77±0.17▲▲ | 0.65±0.15** | 0.80±0.16▲▲ | 0.48±0.12**△△ |
| ULK1 | 2.45±0.83 | - | 1.18±0.53▲▲ | 1.63±0.82** | 1.13±0.37▲▲ | 2.11±0.79**△△ |
Tab.7 Comparison of AMPK, mTOR, HIF-1α, and ULK1 among the 3 groups of participants (Mean±SD)
| Index | Normal (n=30) | Control (n=31) | Observation (n=31) | |||
|---|---|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |
| AMPK | 1.65±0.61 | - | 0.86±0.22▲▲ | 1.26±0.55** | 0.93±0.22▲▲ | 1.50±0.24**△△ |
| mTOR | 0.73±0.27 | - | 1.17±0.27▲▲ | 1.00±0.07** | 1.24±0.27▲▲ | 0.85±0.13**△△ |
| HIF-1α | 0.45±0.10 | - | 0.77±0.17▲▲ | 0.65±0.15** | 0.80±0.16▲▲ | 0.48±0.12**△△ |
| ULK1 | 2.45±0.83 | - | 1.18±0.53▲▲ | 1.63±0.82** | 1.13±0.37▲▲ | 2.11±0.79**△△ |
| Index | Control | Observation | ||
|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |
| CD4+(%) | 26.05±5.77 | 44.54±5.66** | 25.67±5.31 | 57.12±5.41**△△ |
| CD8+(%) | 46.45±9.87 | 30.32±3.87** | 44.66±9.38 | 24.04±2.27**△△ |
| CD4+/CD8+ | 0.56±0.03 | 1.47±0.04** | 0.58±0.04 | 2.38±0.02**△△ |
Tab.8 Comparison of immune function related indicators between the two groups of SLE patients (n=31, Mean±SD)
| Index | Control | Observation | ||
|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |
| CD4+(%) | 26.05±5.77 | 44.54±5.66** | 25.67±5.31 | 57.12±5.41**△△ |
| CD8+(%) | 46.45±9.87 | 30.32±3.87** | 44.66±9.38 | 24.04±2.27**△△ |
| CD4+/CD8+ | 0.56±0.03 | 1.47±0.04** | 0.58±0.04 | 2.38±0.02**△△ |
| [1] | Durcan L, O’Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults[J]. Lancet, 2019, 393(10188): 2332-43. doi:10.1016/s0140-6736(19)30237-5 |
| [2] | Gasparotto M, Gatto M, Binda V, et al. Lupus nephritis: clinical presentations and outcomes in the 21st century[J]. Rheumatology, 2020, 59(): v39-51. doi:10.1093/rheumatology/keaa381 |
| [3] | Caster DJ, Powell DW. Utilization of biomarkers in lupus nephritis[J]. Adv Chronic Kidney Dis, 2019, 26(5): 351-9. doi:10.1053/j.ackd.2019.09.001 |
| [4] | 李 明, 尚双双, 李云飞, 等. 芪黄健脾滋肾颗粒治疗脾肾亏虚型系统性红斑狼疮的临床疗效观察[J]. 时珍国医国药, 2023, 34(2): 370-3. doi:10.3969/j.issn.1008-0805.2023.02.31 |
| [5] | 钱 爱, 程园园, 朱雅文, 等. 芪黄健脾滋肾颗粒治疗系统性红斑狼疮的疗效观察[J]. 安徽中医药大学学报, 2023, 42(6): 7-12. doi:10.3969/j.issn.2095-7246.2023.06.003 |
| [6] | 李云飞, 庞利君, 束龙武, 等. 芪黄健脾滋肾方在脾肾两虚型系统性红斑狼疮患者达标治疗中的临床疗效观察[J]. 中药药理与临床, 2024, 40(11): 62-6. |
| [7] | Cheng Q, Mou LJ, Su WJ, et al. Ferroptosis of CD163+ tissue-infiltrating macrophages and CD10+ PC(+) epithelial cells in lupus nephritis[J]. Front Immunol, 2023, 14: 1171318. doi:10.3389/fimmu.2023.1171318 |
| [8] | Cheng Y, Liu L, Ye Y, et al. Roles of macrophages in lupus nephritis. Front Pharmacol. 2024 Nov 14;15:1477708. doi:10.3389/fphar.2024.1477708 |
| [9] | Hung CM, Lombardo PS, Malik N, et al. AMPK/ULK1-mediated phosphorylation of Parkin ACT domain mediates an early step in mitophagy[J]. Sci Adv, 2021, 7(15): eabg4544. doi:10.1126/sciadv.abg4544 |
| [10] | Hu YQ, Chen H, Zhang LY, et al. The AMPK-MFN2 axis regulates MAM dynamics and autophagy induced by energy stresses[J]. Autophagy, 2021, 17(5): 1142-56. doi:10.1080/15548627.2020.1749490 |
| [11] | Aringer M, Costenbader KH, Dörner T, et al. Response to: ''2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus' by Aringer et Al' by Cui et al[J]. Ann Rheum Dis, 2022, 81(9): e166. doi:10.1136/annrheumdis-2020-218615 |
| [12] | 路志正. 实用中医风湿病学[M]. 北京: 人民卫生出版社, 1996: 490-497. |
| [13] | 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:20. |
| [14] | 姜 泉. 实用中医风湿免疫病学[M]. 北京: 中国中医药出版社, 2022. |
| [15] | Ding T, Yi TT, Li Y, et al. Luteolin attenuates lupus nephritis by regulating macrophage oxidative stress via HIF-1α pathway[J]. Eur J Pharmacol, 2023, 953: 175823. doi:10.1016/j.ejphar.2023.175823 |
| [16] | Bai ZR, Lu ZM, Liu R, et al. Iguratimod restrains circulating follicular helper T cell function by inhibiting glucose metabolism via Hif1α-HK2 axis in rheumatoid arthritis[J]. Front Immunol, 2022, 13: 757616. doi:10.3389/fimmu.2022.757616 |
| [17] | 褚福瑞. 芪黄健脾滋肾颗粒体内外物质基础及对系统性红斑狼疮的网络药理学研究[D]. 合肥: 安徽中医药大学, 2023. |
| [18] | Chen HY, Chiang YF, Hong YH, et al. Quercetin ameliorates renal injury and pyroptosis in lupus nephritis through inhibiting IL-33/ST2 pathway in vitro and in vivo [J]. Antioxidants, 2022, 11(11): 2238. doi:10.3390/antiox11112238 |
| [19] | Song ZY, Ji LN, Wu S, et al. Molecular mechanism of QH-BJ drug pair in the treatment of systemic lupus erythematosus based on network pharmacology and molecular docking[J]. Medicine, 2022, 101(48): e32062. doi:10.1097/md.0000000000032062 |
| [20] | Guo MF, Dai YJ, Gao JR, et al. Uncovering the mechanism of Astragalus membranaceus in the treatment of diabetic nephropathy based on network pharmacology[J]. J Diabetes Res, 2020, 2020: 5947304. doi:10.1155/2020/5947304 |
| [21] | O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists[J]. Nat Rev Immunol, 2016, 16(9): 553-65. doi:10.1038/nri.2016.70 |
| [22] | Orecchioni M, Ghosheh Y, Pramod AB, et al. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages[J]. Front Immunol, 2019, 10: 1084. doi:10.3389/fimmu.2019.01084 |
| [23] | Ma ZW, Li L, Livingston MJ, et al. p53/microRNA-214/ULK1 axis impairs renal tubular autophagy in diabetic kidney disease[J]. J Clin Invest, 2020, 130(9): 5011-26. doi:10.1172/jci135536 |
| [24] | Ba X, Huang Y, Shen P, et al. WTD attenuating rheumatoid arthritis via suppressing angiogenesis and modulating the PI3K/AKT/mTOR/HIF-1α pathway[J]. Front Pharmacol, 2021, 12: 696802. doi:10.3389/fphar.2021.696802 |
| [25] | Wang SY, Liu RC, Yu Q, et al. Metabolic reprogramming of macrophages during infections and cancer[J]. Cancer Lett, 2019, 452: 14-22. doi:10.1016/j.canlet.2019.03.015 |
| [26] | Liang CL, Wei YY, Chen Y, et al. Zhen-Wu-Tang ameliorates lupus nephritis by diminishing renal tissue-resident memory CD8+ T cells via suppressing IL-15/STAT3 pathway[J]. Biomed Pharmacother, 2024, 174: 116597. doi:10.1016/j.biopha.2024.116597 |
| [27] | Escalona E, Olate-Briones A, Albornoz-Muñoz S, et al. Neu1 deficiency and fibrotic lymph node microenvironment lead to imbalance in M1/M2 macrophage polarization[J]. Front Immunol, 2024, 15: 1462853. doi:10.3389/fimmu.2024.1462853 |
| [28] | Yuan YX, Hu RC, Park J, et al. Macrophage-derived chemokine CCL22 establishes local LN-mediated adaptive thermogenesis and energy expenditure[J]. Sci Adv, 2024, 10(26): eadn5229. doi:10.1126/sciadv.adn5229 |
| [29] | Cai WW, Cheng JW, Zong SY, et al. The glycolysis inhibitor 2-deoxyglucose ameliorates adjuvant-induced arthritis by regulating macrophage polarization in an AMPK-dependent manner[J]. Mol Immunol, 2021, 140: 186-95. doi:10.1016/j.molimm.2021.10.007 |
| [30] | Yuan SW, Zeng YT, Li JW, et al. Phenotypical changes and clinical significance of CD4+/CD8+ T cells in SLE[J]. Lupus Sci Med, 2022, 9(1): e000660. doi:10.1136/lupus-2022-000660 |
| [31] | Geng R, Shang HJ, Chen ZQ, et al. ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancer[J]. Biomaterials, 2026, 326: 123677. doi:10.1016/j.biomaterials.2025.123677 |
| [32] | Bai LX, Feng CJ, Xu X, et al. Investigation of the immunomodulatory effects and molecular mechanisms of cichoric acid on cyclophosphamide-induced immunosuppression in mice[J]. Int Immunopharmacol, 2026, 168(Pt 1): 115865. doi:10.1016/j.intimp.2025.115865 |
| [33] | 钱 爱. 基于AMPK/ULK1信号通路调控巨噬细胞M1/M2极化途径探讨芪黄健脾滋肾颗粒对SLE肾损害的干预机制[D]. 合肥: 安徽中医药大学, 2025. |
| [1] | Zaoqiang LIN, Mengyao JIANG, Liuchang FENG, Kunyang FANG, Pingjun FANG, Qinxiang TAN. Rehmanniae radix preparata alleviates chronic kidney disease in mice through a multi-target mechanism [J]. Journal of Southern Medical University, 2026, 46(7): 1611-1621. |
| [2] | Yuanyuan CHENG, Chuanbing HUANG, Juan ZHANG, Yawen ZHU, Ai QIAN. Chonggu Granules attenuate cartilage injury in knee osteoarthritis patients with liver-kidney deficiency syndrome by regulating the Nrf2 pathway [J]. Journal of Southern Medical University, 2026, 46(5): 1028-1038. |
| [3] | Liang HAN, Baichao LI, Bingzhe WANG, Zhiwei ZHANG, Jiuna ZHANG. Cephaeline attenuates malignant biological behaviors of colorectal cancer by regulating the Ras signaling pathway [J]. Journal of Southern Medical University, 2026, 46(5): 1121-1130. |
| [4] | Yunfei LI, Chuanbing HUANG, Lijun PANG, Ziheng ZHU, Ming LI. Jianpi Zishen Formula improves renal damage in mice with systemic lupus erythematosus by inhibiting p53-MDM2 signaling axis-mediated ferroptosis [J]. Journal of Southern Medical University, 2026, 46(4): 785-793. |
| [5] | Yang MA, Longhui GUO, Jinguo WANG, Wenpin XIAO, Yuncheng LV, Xiaoming FAN. Scutellarin improves metabolic dysfunction-associated steatotic liver disease in rats by regulating MMP7 and LCN2 [J]. Journal of Southern Medical University, 2026, 46(4): 907-922. |
| [6] | Jie XIAO, Lingyue JIN, Lina DUAN, Ying GONG, Haixia LI. Streptococcus salivarius-derived extracellular vesicles exacerbate progression of lupus nephritis by activating natural killer cells [J]. Journal of Southern Medical University, 2026, 46(3): 541-549. |
| [7] | Zhaoyong LI, Fenghua ZHOU, Xiaomin SUN, Huashan ZHAO, Yao JIN, Peikun HE, Yuhua JIA. Jiangzhi Quban Recipe improves type 2 diabetes mellitus complicated with hyperlipidemia by multi-target regulation of the inflammation-metabolism network: network pharmacology analysis and clinical validation [J]. Journal of Southern Medical University, 2026, 46(1): 83-93. |
| [8] | Qin HU, Hua JIN. Qingshen Granules improves renal function of patients with chronic kidney disease damp-heat syndrome by activating the miR-23b and Nrf2 pathway [J]. Journal of Southern Medical University, 2025, 45(9): 1867-1879. |
| [9] | Ziwei YANG, Chang LÜ, Zhu DONG, Shulei JI, Shenghui BI, Xuehua ZHANG, Xiaowu WANG. Rosa laevigata Michx. inhibits pulmonary arterial smooth muscle cell proliferation in hypertension by modulating the Src-AKT1 axis [J]. Journal of Southern Medical University, 2025, 45(9): 1889-1902. |
| [10] | Qi YUN, Ruoli DU, Yuying HE, Yixin ZHANG, Jiahui WANG, Hongwei YE, Zhenghong LI, Qin GAO. Cinnamic acid ameliorates doxorubicin-induced myocardial injury in mice by attenuating cardiomyocyte ferroptosis via inhibiting TLR4 [J]. Journal of Southern Medical University, 2025, 45(9): 1946-1958. |
| [11] | Lu RAO, Jiahe DING, Jiangping WEI, Yong YANG, Xiaomei ZHANG, Jirui WANG. Flos Sophorae improves psoriasis in mice by inhibiting the PI3K/AKT pathway [J]. Journal of Southern Medical University, 2025, 45(9): 1989-1996. |
| [12] | Zhongfu TANG, Chuanbing HUANG, Ming LI, Lili CHENG, Junjie CHEN, Shuangshuang SHANG, Sidi LIU. Qihuang Jianpi Zishen Granules ameliorate renal damage in MRL/lpr mice by inhibiting the MyD88/NF-κB pathway [J]. Journal of Southern Medical University, 2025, 45(8): 1625-1632. |
| [13] | Xinyuan CHEN, Chengting WU, Ruidi LI, Xueqin PAN, Yaodan ZHANG, Junyu TAO, Caizhi LIN. Shuangshu Decoction inhibits growth of gastric cancer cell xenografts by promoting cell ferroptosis via the P53/SLC7A11/GPX4 axis [J]. Journal of Southern Medical University, 2025, 45(7): 1363-1371. |
| [14] | Liming WANG, Hongrui CHEN, Yan DU, Peng ZHAO, Yujie WANG, Yange TIAN, Xinguang LIU, Jiansheng LI. Yiqi Zishen Formula ameliorates inflammation in mice with chronic obstructive pulmonary disease by inhibiting the PI3K/Akt/NF-κB signaling pathway [J]. Journal of Southern Medical University, 2025, 45(7): 1409-1422. |
| [15] | Yinfu ZHU, Yiran LI, Yi WANG, Yinger HUANG, Kunxiang GONG, Wenbo HAO, Lingling SUN. Therapeutic mechanism of hederagenin, an active component in Guizhi Fuling Pellets, against cervical cancer in nude mice [J]. Journal of Southern Medical University, 2025, 45(7): 1423-1433. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||